Recombinant anti-Human CD3 mAb(Cat. No.:GMP-A018) novoprotein
$50.00
In stock
SKU
GMP-A018
50μg: Inquiry
500μg: Inquiry
1mg: Inquiry
Description
Recombinant Anti-Human CD3 mAb is a T cell-activated antibody produced based on OKT3 through humanization modification and genetic engineering. On the premise of maintaining the activation ability of OKT3 monoclonal antibody on T cells, the product can eliminate the immunogenicity of murine antibodies to the greatest extent. The product recognizes the human TCR ε chain to activate the T cell activation signaling pathway, thus stimulating T cell activation and proliferation.
Recombinant Anti-Human CD3 mAb is expressed by mammalian cells, and is produced with raw materials of pharmaceutical applicable level. The host protein residue, nucleic acid residue and common pathogens are strictly controlled, and the production and quality management procedures of the product comply with GMP regulations to ensure the traceability of the production process and all raw materials.
Usage
In-vitro cultivation of various types of cell.
Recombinant Anti-Human CD3 mAb can satisfy most T cell expansion requirements and exhibit the same effects as OKT3. For difficult-to-expand cells, the product can be used in combination with Recombinant Anti-Human CD28 mAb (Cat. No: GMP-A063) or NovoNectin® GMP Grade (Cat. No.: GMP-CH38).
Quality Control
| Item | Standard |
| Appearance | Transparent liquid |
| Visible particle | Conform to ChP |
| pH value | 6.5–7.5 |
| Purity | ≥ 95% |
| Bioactivity | 1-10 ng/mL |
| Endotoxin | < 10 EU/mg |
| Host protein | ≤ 0.005% |
| Exogenous DNA residue | ≤ 100 pg/mg |
| Mycoplasma test | Negative |
| Sterility test | Conform to ChP |
Product Details
| Item | Details |
| Storage | Storage at -20±5℃, expiration date labeled on bottle. |
| Recommendations | （1）Make sure the product properly stored and none expired before using. （2）Sterile condition without pyrogen is required for reconstitution, re-aliquoting, dilution. （3）After reconstitution, aliquoted solution vials should be stored at -70°C and minimize freeze-thaw cycles preventing denaturation of protein. Applications in T cell activation and expansion: General applications: The recommended concentration is 5–10 μg/mL; if necessary, the optimal concentration for specific cells can be selected at 5–20 μg/mL. Coating of culture flask: a.Calculate the volume on the basis of 150 μL/cm2, dilute the Recombinant Anti-Human CD3 mAb, recombinant anti-CD28 mAb, and NovoNectin® GMP Grade with normal saline to 5–10 μg/mL, 5–10 μg/mL, and 25–50 μg/mL, respectively, and mix them to a coating solution; b.Add the diluted coating solution to a culture flask or bag and cover the bottom with the solution; c.Place the solution in a 37 °C incubator for 5–8 h, or at 2–5 °C overnight; d.Remove the liquid and wash the flask or bag 3 times with normal saline; e.The well-coated culture vessel shall be used immediately; if the vessel is to be used after more than 30 minutes, store it in normal saline. |
title: Deoxyelephantopin, a natural sesquiterpene lactone, suppresses IL-2 production of ConA-activated T lymphocytes through inhibiting NF-κB and calcineurin/NFAT signaling
authors: Min Cai, Ruijuan Qi, Muqing Wang, Congyu Wu, Qian Chen, Yilin Guo, Yu Liu, Xin Huang, Yuan Gao, Yun Qi
date: 2026/05/30
journal: EUROPEAN JOURNAL OF PHARMACOLOGY
title: Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy
authors: Haigang Geng, Hongye Wang, Chuanjie Zhang, Yangyang Zhou, Yiqing Zhong, Zhenhua Zhu, Zhaorong Wu, Tangansu Zhang, Nuo Xu, Zhongyi Dong, Haoyu Zhang, Qian Li, Yan Li, Xiangyu Tang, Xifu Cheng, Xiang Xia, Zizhen Zhang, Bo Zhai, Zhigang Zheng, Qing Li, Chen Yang, Chunchao Zhu
date: 2026/03/26
journal: DEVELOPMENTAL CELL
title: KRASG12V/HLA-A*02:01–targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors
authors: Huimin Shao, Fei Xu, Jiangyue Xu, Lingjie Zhou, Yao Wu, Lianjun He, Xueyi Qian, Weijie He, Nanlin Jiao, Yabin Xia, Jun Zhao, Lili Sheng, Guoliang Mao, Tao Ma, Wei Wang, Shaoxiang Luo, Li Fu, Zhenyu Xu
date: 2026/2/20
journal: Science Advances
title: Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
authors: Du Sicheng, Zhang Ying, Hao Ruidong, Qiu Lupeng, Li Chao, Li Yuting, Liu Rong-Rui, Zhao Chuan-Hua, Li Juan, Ye Sisi, Zhou Jun, Li Yantao, Yi Qiaoyong, Zhang Shuangshuang, Sun Minmin, Luo Tianhang, Xu Jianming
date: 2025/11/28
journal: MOLECULAR CANCER THERAPEUTICS
title: Dysfunctional glycolysis-UCP2-fatty acid oxidation promotes CTLA4intFOXP3int regulatory T-cell production in rheumatoid arthritis
authors: Han Jiawen, Zhou Zhongyang, Wang Hongxia, Chen Yuxin, Li Wuguo, Dai Meiqin, Bian Jing, Zhao Erming, He Jiaying, Zhang Xinyao, Yi Huanfa, Shao Lan
date: 2025/10/09
journal: MOLECULAR MEDICINE
title: Synthetic NKG2D receptor (SNR) armored CAR-T cells overcome antigen heterogeneity of solid tumor
authors: Sun Minmin, Bian Linke, Wang Hongye, Liu Xin, Li Yantao, Wu Zhaorong, Zhang Shuangshuang, Hao Ruidong, Xin Hong, Zhai Bo, Zhang Xuemei, Cheng Yuanguo
date: 2025/06/19
journal: CELLULAR ONCOLOGY
title: IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment
authors: Wu Zhaorong, Wang Hongye, Zheng Zhigang, Lin Yan, Bian Linke, Geng Haigang, Huang Xiaorong, Zhu Jiufei, Jing Hongshu, Zhang Yi, ji Chen, Zhai Bo
date: 2025/03/05
journal: Journal of Translational Medicine
title: A Universal Therapeutic Vaccine Leveraging Autologous Pre-Existing Immunity to Eliminate in Situ Uniformly Engineered Heterogeneous Tumor Cells
authors: Fuhua Wu, Zhaofei Guo, Jialiang Yang, Yangsen Ou, Xiejin Xie, Hu Liao, Chenqi Guo, Yuxi Zhan, Haiping Wu, Rui Hu, Yanhua Xu, Xue Tang, Haolin Wang, Lin Ye, Penghui He, Chunting He, Lu Huang, Shuang Luo, Xun Sun, Zhenglin Yang
date: 2025/01/21
journal: ADVANCED MATERIALS
title: YAP1 mediates the dimensional and chemical coordination of immunoregulation and therapy in extensively passaged mesenchymal stem cells
authors: Fang-Ying Du, Feng Zhou, Na Zhao, Lei Bao, Cheng-Biao Hu, Jing Lei, An-Qi Liu, Ying-Feng Gao, Li-Hui Bao, Hua Ni, Xiao-Rui Yu, Ji Chen, Bing-Dong Sui
date: 2025/01/06
journal: Theranostics
title: Adipose-derived mesenchymal stem cells combined with platelet-rich plasma are superior options for the treatment of osteoarthritis
authors: He Weijie, Zhao Jie, Liu Jiafei, Wang Fangxing, Xu Zhenyu
date: 2025/01/02
journal: Journal of Orthopaedic Surgery and Research
title: The E3 ubiquitin ligase FBXO38 maintains the antitumor function of natural killer cells by sustaining IL-15R signaling
authors: Shi Yongjing, Zheng Xiaodong, Peng Hui, Xu Chenqi, Sun Rui, Tian Zhigang, Sun Haoyu, Wang Xianwei
date: 2024/07/11
journal: Cancer Immunology Research
title: Anti-angiogenesis and anti-immunosuppression gene therapy through targeting COUP-TFII in an in situ glioblastoma mouse model
authors: Wang Fei, Zhang Shuo, Sun Fengjiao, Chen Weiwei, Liu Cuilan, Dong Hongliang, Cui Bingjie, Li Lingyu, Sun Chunlong, Du Wen, Liu Bin, Fan Wanfeng, Deng Jiong, Schmitt Clemens A., Wang Xiuwen, Du Jing
date: 2024/06/26
journal: CANCER GENE THERAPY
title: Distinct biological characteristics of mesenchymal stem cells separated from different components of human placenta
authors: Xiangxiong Deng, Su Zhang, Quan Qing, Pengfei Wang, Haiyang Ma, Qinghua Ma, Weixiang Zhao, Hanjing Tang, Min Lu
date: 2024/06/13
journal: Biochemistry and Biophysics Reports
title: CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
authors: Wei Ye, Xu Tingting, Li Chong, Zhou Xin, Qian Wei, Shen Chunying, Wang Qifeng, Xing Xing, Ou Xiaomin, He Xiayun, Yin Hongmei, Hu Chaosu, Wang Yu, Ji Qinghai, Su Fengtao, Lu Xueguan
date: 2023
journal: Cancer Immunology Research
title: Hsa_circ_0073453 modulates IL-8 secretion by GC-MSCs to promote gastric cancer progression by sponging miR-146a-5p
authors: Chen Wu, Xiaoli Cao, Juan Xu, Lin Wang, Jiaying Huang, Jing Wen, Xiang Wang, Xiao Sang, Wei Zhu, Yongliang Yao, Chenglin Zhou, Feng Huang, Mei Wang
date: 2023
journal: INTERNATIONAL IMMUNOPHARMACOLOGY
title: Epigenetic activation of the TUSC3 gene as a potential therapy for XMEN disease
authors: Haodong Ding, Yuwei Li, Maoxin Fang, Jiaojiao Chen, Lipin Liu, Zhigang Lu, Jia Hou, Min Luo
date: 2023
journal: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
title: Evaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma
authors: Vladimir Babenko, Mei Tang, Caili Chen, Guoqing Wang, Yuelong Wang, Zongliang Zhang, Hexian Li, Qizhong Lu, Zeng Wang, Shasha Zhao, Chen Yang, Kunhong Zhong, Ruyuan Zhang, Liping Guo, Zhu Yuan, Chunlai Nie, Aiping Tong
date: 2022
journal: Biomolecules
title: Optimizing rAAV6 transduction of primary T cells for the generation of anti-CD19 AAV-CAR-T cells
authors: Dongxin Wang, Qungang Zhou, Xiang Qiu, Xiaomei Liu, Chun Zhang
date: 2022
journal: BIOMEDICINE & PHARMACOTHERAPY
title: Delineation of colorectal cancer ligand-receptor interactions and their roles in the tumor microenvironment and prognosis
authors: Lin, Hexin, Xia, Lu, Lian, Jiabian, Chen, Yinan, Zhang, Yiyi, Zhuang, Zhicheng, Cai, HuaJun, You, Jun, Guan, Guoxian
date: 2021
journal: Journal of Translational Medicine
title: Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma
authors: Xin Tang, Fujun Liu, Zhiyong Liu, Yi Cao, Zongliang Zhang, Yuelong Wang, Jianhan Huang, Shuangming Fan, Shasha Zhao, Yaxin Chen, Gaowei Li, Shan Wang, Meijun Zheng, Yating Hu, Hongjian Li, Caiying Jiang, Meijia Yang, Hui Yang, JianGuo Xu, Gang Guo, Aiping Tong, Liangxue Zhou
date: 2020
journal: Clinical & Translational Immunology
title: Three-Dimensional Culture of Umbilical Cord Mesenchymal Stem Cells Effectively Promotes Platelet Recovery in Immune Thrombocytopenia
authors: Xiangcui Gong, Di Sun, Zhenghao Li, Qing Shi, Dong Li, Xiuli Ju
date: 2020
journal: BIOLOGICAL & PHARMACEUTICAL BULLETIN
title: AAVS1 site-specific integration of the CAR gene into human primary T cells using a linear closed-ended AAV-based DNA vector
authors: Wei Chen, Liang Tan, Qungang Zhou, WenSheng Li, Taiming Li, Chun Zhang, Jianxiang Wu
date: 2020
journal: JOURNAL OF GENE MEDICINE
title: Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer:
authors: Feng Yu, Xiaoyan Wang, Hui Shi, Maorong Jiang, Jun Xu, Min Sun, Qinggang Xu, Frank Peprah Addai, Haifeng Shi, Jie Gu, Yang Zhou, Liqiong Liu
date: 2020
journal: Tumori Journal
title: Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response
authors: Changyou Li, Danni Zhu, Yonghui Zhao, Qingming Guo, Weihong Sun, Linxi Li, Daiqing Gao, Peng Zhao
date: 2019
journal: IMMUNOLOGICAL INVESTIGATIONS
title: Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells
authors: Ying Wang, Xijing Yang, Yi Yu, Zenghui Xu, Yan Sun, Hui Liu, Jingbo Cheng, Min Liu, Bibo Sha, Linfang Li, Na Ding, Zhong Li, Huajun Jin, Qijun Qian
date: 2018
journal: Journal of Cancer
title: EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma
authors: Hui Shi, Feng Yu, Yinting Mao, Qianqian Ju, Yingcheng Wu, Wen Bai, Peiwen Wang, Ran Xu, Maorong Jiang, Jiahai Shi
date: 2018
journal: Journal of Thoracic Disease
title: Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC)
authors: Yuanlong Gu, Huimin Lv, Juan Zhao, Qi Li, Guannan Mu, Jiade Li, Jiazi Wuyang, Ge Lou, Ruitao Wang, Yanqiao Zhang, Xiaoyi Huang
date: 2017
journal: INTERNATIONAL IMMUNOPHARMACOLOGY
title: The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors
authors: Wang Ying, Xu Zenghui, Zhou Fuping, Sun Yan, Chen Jingbo, Li Linfang, Jin Huajun, Qian Qijun
date: 2015
journal: Experimental Hematology & Oncology
MDSD
Reviews
Write Your Own Review
Related Products
Check items to add to the cart or
